Aztreonam 1 zthreonam; SQ 26,776) is the first member of a new class of β-lactam antibiotics, the monobactams. Aztreonam is selectively active against Gram-negative aerobic bacteria and inactive against Gram-positive bacteria. Thus, in vitro, aztreonam is inhibitory at low concentrations (MIC 90 ≤ 1.6 mg/L) against Enterobacteriaceae except Enterobacter species, and is active against Pseudomonas aeruginosa, 90% of pseudomonads being inhibited by 12 to 32 mg/L. Aztreonam is inactive against Gram-positive aerobic bacteria and anaerobes, including Bacteroides fragilis. Therefore, when administered alone, aztreonam has minimal effect on indigenous faecal anaerobes. Aztreonam must be administered intravenously or intramuscularly when used to treat systemic infections, since absolute bioavailability is very low (about 1%) after oral administration. Since elimination half-life is less than 2 hours, 6- or 8-hourly administration is used in the treatment of moderately severe or severe infections, although 12-hourly injection is adequate in less severe systemic and some urinary tract infections. Therapeutic trials have shown aztreonam to be effective in Gram-negative infections including complicated infections of the urinary tract, in lower respiratory tract infections and in gynaecological and obstetric, intra-abdominal, joint and bone, skin and soft tissue infections, uncomplicated gonorrhoea and septicaemia. In comparisons with other antibiotics, aztreonam has been at least as effective or more effective than cefamandole in urinary tract infections and similar in efficacy to tobramycin or gentamicin. Where necessary, aztreonam and the standard drug have both been combined with another antibiotic active against Gram-positive and/or anaerobic bacteria. Aztreonam has been effective in eradicating pseudomonal infections in most patients (except in patients with cystic fibrosis), but the inevitably limited number of pseudomonal infections available for study prevents any conclusions as to the relative efficacy of aztreonam compared with other appropriate regimens against these infections. Thus, with an antibacterial spectrum which differs fromthat of other antibiotics, aztreonam should be a useful alternative to aminoglycosides or ‘third generation’ cephalosporins in patients with proven or suspected serious Gram-negative infections.
Aztreonam, a monobactam, is inhibitory in vitro at low concentrations (usually ≤ 1.0 mg/L) against 90% of clinical isolates of the Enterobacteriaceae (except Enterobacter species) as well as Haemophilus influenzae, Neisseria gonorrhoeae, Salmonella and Shigella species. Pseudomonas aeruginosa are generally susceptible to aztreonam, being usually inhibited by 12 to 32 mg/L of the drug. Aztreonam is essentially inactive against Gram-positive bacteria and the important anaerobes.
In comparisons with the third generation cephalosporins and other antibiotics, the activity of aztreonam against the enterobacteriaceae is generally similar to that of cefotaxime and ceftazidime and greater than that of cefoperazone, cefoxitin, gentamicin, tobramycin or piperacillin. Against P. aeruginosa, aztreonam is generally similar in activity to cefoperazone, more active than cefotaxime, latamoxef (moxalactam) and ceftizoxime and usually less active than ceftazidime. The inhibitory activity of imipenem against P. aeruginosa is consistently greater than that of aztreonam.
In common with third generation cephalosporins and latamoxef, aztreonam is stable to hydrolysis by a wide range of β-lactamases, but not against Class I cephalosporinases.
The minimum bactericidal concentration of aztreonam is generally equal to or 2 to 4 times the minimum inhibitory concentration for most strains tested, although for P. aeruginosa the MBC/MIC ratio varied over a wider range. Aztreonam has a high binding affinity for penicillin binding protein 3 and thus produces elongated bacterial forms that are unable to grow.
An increase in the inoculum size to 106fu or the addition of up to 75% human serum to the growth media had little effect on the MIC of aztreonam for tested strains of susceptible E. coli and Klebsiella species.
A combination of aztreonam and an aminoglycoside has been synergistic against up to 96% of strains of Pseudomonas species, but most often against 50% of tested strains.
In vivo, the activity of aztreonam has been demonstrated in a variety of experimental Gram-negative bacterial infections in animals and was similar to that of cefotaxime and ceftazidime against pseudomonal infections and H. influenzae meningitis. In this latter model, aztreonam was more effective in eliminating ampicillin-resistant strains than chloramphenicol.
Aztreonam is completely absorbed after intramuscular injection but less than 1% of an orally administered dose is available to the systemic circulation. Mean plasma concentrations generally increase linearly with dosage after intravenous or intramuscular administration and are about 58, 125, 242 and 455 mg/L 10 minutes after bolus intravenous injection of single doses of 0.5, 1.0, 2.0 and 4.0g, respectively. Single-dose intramuscular administration of lg results in a mean peak plasma concentration of about 46 to 66 mg/L. After the first hour, plasma concentrations of aztreonam are comparable whether aztreonam is administered intravenously or intramuscularly. There is no evidence of accumulation in healthy subjects given repeated intravenous or intramuscular doses at 8-hourly intervals.
Volume of distribution at steady-state is 0.15 to 0.18 L/kg (total drug) and 0.4 L/kg for the free drug. Following usual parenteral doses aztreonam is present in prostatic tissue, cerebrospinal fluid (inflamed meninges) and skin blister fluid at peak concentrations many times higher than required to inhibit susceptible enterobacteriaceae. Aztreonam reaches the placenta and is present in breast milk, but since the bioavailability of oral aztreonam is very low there is little likelihood of side effects in breast-fed infants of mothers treated with the drug. Binding of aztreonam to plasma proteins has been reported to be between 56 and 60%. Aztreonam is metabolised to a limited extent, there being no evidence of microbiologically active metabolites. Excretion is mainly via the urine, with high urinary concentrations of around 3000 mg/L occurring during the first 2 hours after intravenous administration of a lg dose. The elimination half-life (t1/2β) of aztreonam in healthy subjects is between 1.3 and 2 hours, while that of the main metabolite (SQ26,992) is about 26 hours. Elimination half-life is prolonged proportionally to the extent of renal impairment and in patients with alcoholic cirrhosis, but appears shorter in patients with cystic fibrosis than in healthy subjects.
Aztreonam alone, and where necessary combined with an antibiotic effective against Gram-positive and/or anaerobic bacteria, has been used successfully to treat infections of the urinary tract and lower respiratory tract, as well as intraabdominal infections, obstetric and gynaecological infections, septicaemia, bone and joint infections and acute uncomplicated gonorrhoea.
In most patients with Gram-negative urinary tract infections there were urological abnormalities or predisposing factors, and infections were usually recurrent. At follow-up 1 to 6 weeks after the end of treatment with aztreonam 1 to 6g daily, 42 to 67% of patients were considered cured. In comparisons with other antibiotics aztreonam was at least as effective as, or more effective than, cefamandole in urinary tract infections and similar in efficacy to the aminoglycosides (gentamicin or tobramycin) in patients with serious urinary tract infections. Four to 6 weeks after the end of treatment, bacteriological cure was achieved in 56 to 93% of patients treated with aztreonam and in 34 to 78% treated with the standard drug.
Aztreonam 3 to 6g daily (usually) was clinically effective in about 90% of patients with lower respiratory tract infections caused by Gram-negative bacteria. Bacteriological cure (other than in patients with cystic fibrosis) was achieved in 67 to 79% of patients. As with other antibiotics, aztreonam was less effective in eradicating the infecting pathogen (P. aeruginosa) in patients with cystic fibrosis than in other patients. In comparisons with tobramycin in patients with respiratory tract infections, aztreonam has been of similar efficacy in two studies and more effective in a third. Aztreonam (usually 6g daily) and tobramycin 3 mg/kg daily were also of similar efficacy in eradiciting postoperative or perioperative intra-abdominal infections, as were aztreonam 6g daily and gentamicin 4.5 mg/kg daily in women with endometritis following caesarean section.
Septicaemia was cured in 67 to 100% of patients treated with aztreonam 4 to 6g daily or 50 to 100 mg/kg daily administered intravenously.
Chronic or acute osteomyelitis was successfully treated in small numbers of patients in whom P. aeruginosa was the most common pathogen and infections of skin and soft tissue were cured in 87% of patients. The frequency of relapse has yet to be adequately determined.
Initial studies in men and women with acute uncomplicated gonorrhoea suggest that aztreonam lg intramuscularly may be a suitable alternative to spectinomycin in patients infected with penicillin-resistant gonococci.
Preliminary studies in healthy subjects that orally administered aztreonam (300mg daily for 5 days) may be suitable for selective elimination of intestinal Gram-negative bacteria, since these organisms were removed without disturbing the commensal yeasts or anaerobes.
Aztreonam has generally been well tolerated, the most frequently reported side effects having been local reactions at the infusion site (1.7%), skin rash (1.8%), nausea and/or vomiting (0.6%) and diarrhoea (0.8%). Superinfection, mostly with Group D streptococci, has been reported in 9.7% of patients, but specific treatment has been required in about half of these infections. Aztreonam appears to have low potential for immunogenicity and also for cross-reactivity with antibodies to other β-lactam antibiotics. Aztreonam has been used safely in patients who are allergic to penicillin.
Dosage and Administration
Aztreonam for injection may be administered intravenously or intramuscularly. Dosage should be determined by the severity of infection and the susceptibility in vitro of the pathogen. As a guide, the usual dose is 0.5 to lg 8- or 12-hourly in urinary tract infections, 1 or 2g 8- or 12-hourly in moderately severe systemic infections and 2g 6- or 8-hourly in severe systemic or life-threatening infections or those caused by P. aeruginosa.
In patients with moderate to severe renal impairment the dosage of aztreonam should be reduced. As a general rule, aztreonam dosage should be halved in patients whose creatinine clearance is between 0.6 and 1.8 L/h, although an initial loading dose of 1 or 2g should be given in such patients.
KeywordsCefotaxime Ceftazidime Tobramycin Aztreonam Cefoperazone
Unable to display preview. Download preview PDF.
- Adam D. Preliminary experience with aztreonam in pediatric infections, Chemioterapia 4(Suppl. 1): 96, 1985Google Scholar
- Adkinson NF, Saxon A, Spence MR, Swabb EA. Cross-allergenicity and immunogenicity of aztreonam. Reviews of Infectious Diseases 7 (Suppl.):1, 1985Google Scholar
- Albertazzi A, Cappelli P, Di Paolo B, Spisni C. Renal safety of aztreonam evaluated by urinary excretion of N-acetyl-β-glucosaminidase. Chemioterapia 4(Suppl. 1): 41, 1985Google Scholar
- Bakhtiar M, Selwyn S. Comparative in vitro studies of aztreonam and other agents used primarily in infections with aerobic Gram-negative bacteria. In Williams & Woods (Eds) Aztreonam the antibiotic discovery for Gram-negative infections. Royal Society of Medicine International Congress and Symposium Series No. 89, pp. 35–45, 1985Google Scholar
- Barbacci MB, Wheeler BB, Adkinson NF, Spence MR, Swabb EA. Comparative trial of aztreonam, cefotaxime and aqueous penicillin G in the treatment of uncomplicated gonorrhoea. Abstract 1131, 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, 1984Google Scholar
- Barry AL, Thornsberry C, Jones RN, Gavan TL. Aztreonam: antibacterial activity, β-lactamase stability interpretive standards and quality control guidelines for disk diffusion susceptibility. Reviews of Infectious Diseases 7(Suppl. 4): 634–644, 1985Google Scholar
- Barza M, Ferreira MC, Jacobus NV. Activity in vitro of SQ26,776 a novel Aactamcompound. Abstract no. 884, Paper presented at 21st ICAAC1 1981Google Scholar
- Beam TR, Pasko M, Raab TA. Comparison of aztreonam and ampicillin in experimental E. coli meningitis. Abstract no. 230, 22nd ICAAC, Miami, 1982Google Scholar
- Bendush CL, Henry SA. Aztreonam: worldwide clinical trials results. Chemioterapia 4(Suppl. 1): 102, 1985Google Scholar
- Berry AJ, Duma RJ, Ramsey KM, Baggett JW, Swabb EA. et al. Penetration of aztreonam (SQ26,776) into human cerebrospinal fluid (CSF). Abstract no. 406, ICAAC, Us Vegas, 1983.Google Scholar
- Birolini D, Moraes, MF, de Souza OS. Aztreonam plus clindamycin vs. tobramycin plus clindamycin for the treatment of intra-abdominal infections. Reviews of Infectious Diseases 7(Suppl. 4): 764–768, 1985Google Scholar
- Blandino G, Caccamo F, Dibartolo L, Toscano MA. Effect of different aztreonam concentrations on growth curves and bacterial morphology of Gram-negative bacilli. Chemoterapia 4(Suppl. 1): 32, 1985Google Scholar
- Bodem CR, Laun PR, Strausbaugh LJ. Penetration of aztreonam into cerebrospinal fluid and brain in rabbits. Abstract no 18, 23rd ICAAC, Las Vegas, 1983Google Scholar
- Bodey GP, Jadeja L, Swabb E, Bolivar R, Fainstein V. Pharmacokinetic studies of aztreonam. Abstract no. 411, ICAAC, Las Vegas, 1983Google Scholar
- Bolton ND, Gerig JS, Scheid WM, Swabb EA, Bolton WK. Peritoneal transfer of aztreonam in patients during continuous ambulatory peritoneal dialysis. Kidney International 25: 225, 1984Google Scholar
- Bouza E, Romero Vivas J, Rodriguez-Creixems M, Hellin T, Sanz-Hospital J et al. Evaluation of aztreonam in the treatment of severe infections in non-neutropenic patients. Chemioterapia 4:(Suppl. 1): 84, 1985Google Scholar
- Bremner DA. Aztreonam activity against gram-negative bacilli. Chemotheray 30: 44, 1984Google Scholar
- Cipriani P, Giordano A, Brenciaglia MI, Mancini C, Ghezzi MC, et al. In vitro susceptibility test with aztreonam compared with cefotaxime, cefoxitin, cefuroxime, caphalothin, cefoperazone and gentamicin. Drugs under Experimental Clinical Research 9: 275, 1983Google Scholar
- Clarke AM, Zemcov SJV. Antibacterial activity of the cephamycin cefotetan: an in vitro comparison with other β-lactam antibiotics. Journal of Antimicrobial Chemotherapy II(Suppl. A): 67, 1983Google Scholar
- Cone LA, Woodard DR. Aztreonam therapy for serious gram-negative bacillary infections. Reviews of Infectious Diseases 7(Suppl. 4): 834–842, 1985Google Scholar
- Coombes JD. Metabolism and pharmacokinetics of the newer cephalosporins: cefotaxime, ceftizixime, ceftriaxone, ceftazidime, cefoperazone, moxalactam and cefsulodin. In Neu (Ed.) New beta-lactam antibiotics. Proceedings of the Cephalosporins Symposium of the American College of Clinical Pharmacology, pp. 177–214, 1982Google Scholar
- Cox CE. Aztreonam therapy of complicated urinary tract infections due to multidrug-resistant bacteria. Chemioterapia 4(Suppl. 1): 46, 1985Google Scholar
- Cran S, Van Laethem Y, Van de Perre P, Jasper N, Gordts B, et al. Aztreonam in severe gram-negative septicemia. Chemioterapia 4(Suppl. 1): 70, 1985Google Scholar
- Dodson MG, Faro, S. The polymicrobial etiology of acute pelvic inflammatory disease and treatment regimens. Reviews of Infectious Diseases 7(Suppl. 4): 736–742, 1985Google Scholar
- Easmon CSF, Ison CA, Gedney J. In vitro activity of aztreonam against penicillin- and spectinomycin-resistant Neisseria gonorrhoeae. In Williams & Woods (Eds) Aztreonam the antibiotic discovery for Gram-negative infections. Royal Society of Medicine International Congress and Symposium Series No. 89, pp. 75–78, 1985Google Scholar
- Elliot TSJ, Greenwood D. The morphological response of Pseudomonas aeruginosa to azthreonam, cefoperazone, ceftazidime and N-formimidoyl thienamycin. Journal of Medical Microbiology 17: 159, 1984Google Scholar
- Everett DW, Weinstein SH, Walker BD, Funke PT, Migdalof BH. Isolation and idientification of the major metabolite of l4C-aztreonam in human urine. Abstract no. 26. Pharmacologist 25(3): 115, 1983Google Scholar
- Frimodt-Møller PC, Madsen PO. A comparative study of aztreonam and tobramycin in treatment of complicated urinary tract infections. Paper presented at 13th International Congress of Chemotherapy, Vienna, 1983Google Scholar
- Garcia-Rodriguez JA, Capurro M, Prieto J. The use of aztreonam in high risk patients in the intensive care unit. Paper presented at the 13th International Congress of Chemotherapy, Vienna, 1983Google Scholar
- Giamarellou H, Douzinas E, Koratzanis G, Daourou A. In vitro studies with aztreonam. Chemioterapia 2: 325, 1983Google Scholar
- Gibbs RS, Blanco JD. A comparison of aztreonam plus clindamycin with gentamicin plus clindamycin in the treatment of endometrtis after cesarean section. Paper presented at the 13th International Congress of Chemotherapy, Vienna, 1983Google Scholar
- Gibbs RS, Blanco JD, St Clair PJ, Lipscombe KA. A comparison of aztreonam plus clindamycin with gentamicin plus clindamycin in the treatment of endometritis after cesarean section. Chemioterapia 4(Suppl. 1): 44, 1985Google Scholar
- Gobernado M, Santos M, Marco V, Mascaros E. Efficacy of azthreonam in the treatment of gram negative pneumonia and sepsis. Paper presented at the 13th International Congress of Chemotherapy, Vienna, 1983Google Scholar
- Gudiol F. Clinical evaluation of aztreonam in gram-negative septicemia. Chemioterapia 4(Suppl. 1): 67, 1985Google Scholar
- Hara K, Kobayashi H, Nishiura T, Yura J, Saito A. Clinical studies of aztreonam in Japan. Reviews of Infectious Diseases 7(Suppl. 4): 850–863, 1985Google Scholar
- Harrison WO. Aztreonam as therapy for gonococcal urethritis. Reviews of Infectious Diseases 7(Suppl. 4), 1985Google Scholar
- Hartman BJ, Roberts RB. Aztreonam in the therapy of serious gram negative bacterial infection in burn unit patients and other hospitalised patients. Paper presented at the 13th International Congress of Chemotherapy, Vienna, 1983Google Scholar
- Hayashi R, Devlin RG, Frantz M, Stern M. Concentration of aztreonam in body fluids in mid-pregnancy. Abstract no. 111-C. Clinical Pharmacology and Therapeutics 35: 246, 1984Google Scholar
- Henry SA. Overall clinical experience with aztreonam in the treatment of intra-abdominal infections. Reviews of Infectious Diseases 7(Suppl. 4): 769–773, 1985aGoogle Scholar
- Henry SA. Overall clinical experience with aztreonam in obstetric-gynecologic infections. Reviews of Infectious Diseases 7(Suppl. 4): 743–748, 1985bGoogle Scholar
- Hobson D, Lee N, Bushell AC, Withana N. The activity of β-lactam antibiotics against Chlamydia trachomatis in McCoy cell cultures. In Mardh et al. (Eds) Chlamydial Infections, p. 249, Proceedings of 15th International Symposium on human chlamydial infections, Sweden, June, 1982Google Scholar
- Hodder RW. Aztreonam for the treatment of urinary tract infection: European experience. In Williams & Woods (Eds) Aztreonam the antibiotic discovery for Gram-negative infections. Royal Society of Medicine International Congress and Symposium Series, No. 89, pp. 47–56, 1985Google Scholar
- Janicke DM, Cafarell RF, Parker SW, Apicella MA, Jusko WJ. Pharmacokinetics of aztreonam (SQ26,776) in infected patients. Abstract of paper presented at the 13th International Congress of Chemotherapy, 1983Google Scholar
- Jones P, Rolston K, Fainstein V, Elting L, Body GP. Aztreonam plus vancomycin (plus amikacin) vs moxalactam plus ticarcillin for the empiric treatment of febrile episodes in neutropenic cancer patients. Review of Infectious Diseases 7(Suppl. 4): 781–786, 1985bGoogle Scholar
- Le Bel M, Paone RP, Lewis GP. Lack of interference of five new β-lactam antibiotics with serum creatinine determination. Drug Intelligence and Clinical Pharmacy 17: 908, 1983Google Scholar
- Le Bel M, Paone RP, Lewis GP. Effect of ten new β-lactam antibiotics on urine glucose test methods. Drug Intelligence and Clinical Pharmacy 18: 617, 1984Google Scholar
- Lerner SA, Dudek EJ, Boisvert WE, Berndt KD. Effect of highly potent antipseudomonal β-lactam agents alone and in combination with aminoglycosides against Pseudomonas aeruginosa. Reviews of Infectious Diseases 6(Suppl. 3): 678, 1984Google Scholar
- Louie TJ, Chubb H, Bow EJ, Conly JM, Harding GKM, et al. Effect of aztreonam plus cloxacillin, aztreonam plus tobramycin or moxalactam plus tobramycin on colonization resistance parameters during embiric therapy of febrile neutropenic episodes. Chemioterapia 4(Suppl. 1): 107, 1985aGoogle Scholar
- Louie TJ, Chubb H, Bow EJ, Conly JM, Harding GKM, et al. Preservation of colonisation resistance parameters during empiric therapy with aztreonam in febrile neutropenc episodes. Reviews of Infectious Diseases 7(Suppl. 4): 787–801, 1985bGoogle Scholar
- McKellar PP. Clinical evaluation of aztreonam therapy for serious infections due to gram-negative bacteria. Reviews of Infectious Diseases 7(Suppl. 4): 843–849, 1985Google Scholar
- Martelli A, Cortecchia V, Ventriglia L. Multicentre study in patients with urinary tract infections treated with aztreonam. Chemioterapia 4(Suppl. 1): 51, 1985Google Scholar
- McLean KA, Harris JRW. Treatment of uncomplicated anogenital gonorrhoea with single dose aztreonam. In Williams & Woods (Eds) Aztreonam the antibiotic discovery for Gram-negative infections. Royal Society of Medicine International Congress and Symposium series No. 89, pp. 69–74, 1985Google Scholar
- Mogabgab WJ, Lutz B, Thurm R, Newman T, Beville R. A comparison of aztreonam and spectinomycin for the treatment of gonorrhoea. Paper presented at the 13th International Congress of Chemotherapy, Vienna, 1983Google Scholar
- Mokhbat JE, Munyan MM, Pruett TL, Sabath LD. Clinical evaluation of aztreonam in the treatment of serious gram-negative infections. Paper presented at the 13th International Congress of Chemotherapy, Vienna, 1983Google Scholar
- Nakashima M, Uematsu T, Takashima M. Pharmacokinetics and safety of aztreonam in Japanese healthy volunteers. Paper presented at the 13th International Congress of Chemotherapy, Vienna, 1983Google Scholar
- National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disk Susceptibility Tests M2-A3, 4th ed., Vol. 4, No. 16, NCCLS, Villanova, PA, December, 1984Google Scholar
- Negosanti M, Patrone P, Ghetti P. Aztreonam in patients with acute gonococcal urethritis. Giornale Italiano Di Dermatologia e Venereologia 118: 1, 1983Google Scholar
- Newman TJ, Dreslinski GR, Tadros SS. Safety profile of aztreonam in clinical trials. Reviews of Infectious Diseases 7(Suppl. 4), 1985Google Scholar
- Nolen TM, Phillips HL, Hall HJ, Smith D, Jackson M. A comparison of azthreonam and tobramycin in the treatment of gram negative lower respiratory infections. Paper presented at the 13th International Congress of Chemotherapy, Vienna 1983Google Scholar
- Norrby R, Friberg K, Holm, SE. In vitro antibacterial activity of SQ26,776. Journal of Antimicorbial Chemotherapy 8(Suppl. E): 69, 1981Google Scholar
- Paradelis AG, Tselentis J, Crassaris L, Triantaphyllidis C. In vitro activity of azthreonam (SQ26,776), a new monobactam antibiotic. Drugs in Experimental and Clinical Research 9: 325, 1983aGoogle Scholar
- Paradelis AG, Stathopoulos AG, Tselenths J, Delidou K, Stavrakis A, et al. Comparative antibacterial activity of aztreonam and other antimicrobial agents against gram-negative micro-organisms. Chemoterapia 4(Suppl. 1): 14, 1985Google Scholar
- Parker SW, Cafarell RF, Janicke DM, Jusko WJ, Apicella MA. Clinical efficacy of aztreonam (SQ26,776) in serious gram negative infections. Paper presented at the 13th International Congress of Chemotherapy, Vienna 1983Google Scholar
- Prigogine T, Glupczynski Y, Crokaert F, Schmerber J, Yourassowsky E. Clinical evaluation of aztreonam (AZ) in the therapy of serious gram-negative lower respiratory tract infections. Abstract. 3rd Congress of European Society of Pneumology, Basel, 1984Google Scholar
- Principi N, Dalla Villa A, Landoni R, Reali E, Vigano A. Aztreonam in the treatment of urinary tract infections in children. Chemioterapia 4(Suppl. 1): 99, 1985Google Scholar
- Rabinad E, Dalet F, del Rio G, Brassesco M, Caballé L. Aztreonam concentration in seminal plasma. Abstract 33, 4th Mediterranean Congress of Chemotherapy, Greece, October 1984Google Scholar
- Reed MD, Blumer JL, Friedhoff, LT, Platt TB, Myers CM, et al. Single dose pharmacokinetics of aztreonam in cystic fibrosis. Abstract II-C. Clinical Pharmacology and Therapeutics 37: 223, 1985Google Scholar
- Reeves DS, Bywater MJ, Holt HA, White LO, Davies AJ, et al. Pharmacokinetics of cefoperazone in man. Abstract 113. Paper presented at 20th ICAAC, p. 14, Excerpta Medica, Amsterdam, 1980Google Scholar
- Rehm SJ, Hall GS, Alanis A, Weinstein AJ. In vitro effects of combinations of aztreonam with tobramycin, pipericillin and moxalactam against Pseudomonas aeruginosa and Serratia marcescens. Abstract no. 30, ICACC, Las Vegas, 1983Google Scholar
- Sabbour MS, Osman L, Shaker A, El Messidi M. Experience with some new antibiotics in urinary tract infections. Chemioterapia 4(Suppl. 1): 56, 1985Google Scholar
- Sattler FR, Schramm M, Swabb EA. Safety of aztreonam and SQ26,992 in elderly patients with renal insufficiency. Journal to come, in press, 1984bGoogle Scholar
- Schalkhäuser K, Tüllmann K. Experience with aztreonam in the treatment of complicated urinary tract infections. Paper presented at the 13th International Congress of Chemotherapy, Vienna, 1983Google Scholar
- Scheid WM, Alliegro GM, Brodeur JP. Therapy of experimental ampicillin-resistant Haemophilus influenzae meningitis. Abstract no. 491, 21st ICAAC, Chicago, 1981Google Scholar
- Scheid WM, Brodeur JP, Gratz JC, Foresman P, Rodeheaver G. Evaluation of aztreonam in experimental bacterial meningitis and cerebritis. Antimicrobial Agents and Chemotherapy 24: 682, 1983Google Scholar
- Schentag JJ, Wels PB, Simons GW, Swabb EA, Vigano A, et al. Abdominal fluid penetration of aztreonam versus tobramycin in patients with abdominal sepsis. Abstract. Paper presented at 13th International Congress of Chemotherapy, Vienna 1983Google Scholar
- Scully B, Henry SA. Clinical experience with aztreonam in the treatment of gram-negative bacteraemia. Reviews of Infectious Diseases 7:(Suppl. 4): 829–833, 1985Google Scholar
- Scully BE, Ores CN, Prince AS, Neu HC. Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. Reviews of Infectious Diseases 7(Suppl. 4): 709–714, 1985Google Scholar
- Shinagawa N, Ishikawa S, Yura J, Shibata K. Tissue penetration characteristics of aztreonam compared to cefoxitin in human serum, bile and gallbladder wall. Abstract 587: 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, 1984Google Scholar
- Simons WJ, Lee TJ. Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli. Reviews of Infectious Diseases 7(Suppl. 4): 823–828, 1985bGoogle Scholar
- Strandberg DA, Jorgensen JH, Drutz DJ. Activity of aztreonam and new β-lactam antibiotics against penicillinase-producing Neisseria gonorrhoeae. Current Therapeutic Research 34: 955, 1983bGoogle Scholar
- Stutman HR, Swabb EA, Platt TB, Marks MI. Pharmacokinetics and safety of aztreonam in pediatric patients. Abstract 408, ICAAC, Las Vegas, 1983Google Scholar
- Swabb EA, Sugerman AA, Leitz MA. Renal, tubular handling of azthreonam in healthy subjects. Abstract ICAAC, Miami, 1982bGoogle Scholar
- Swabb EA, Cone CO, Muir JG. Summary of worldwide clinical trials of aztreonam in patients with lower respiratory tract infections. Reviews of Infectious Diseases 7(Suppl. 4): 715–718, 1985bGoogle Scholar
- Swabb EA, Jenkins SA, Muir JG. Summary of worldwide clinical trials of aztreonam in patients with urinary tract infections. Reviews of Infectious Diseases 7(Suppl. 4): 812–817, 1985aGoogle Scholar
- Tanaka SK, Bonner DP, Sykes RB. In vitro activity of aztreonam in combination with aminoglycosides and other β-lactams against gram-positive and Gram-negative bacteria. Paper presented at the 13th International Congress of Chemotherapy SS 4.1/3, 1, 1983Google Scholar
- Torres A, Ramirez-Ronda CH. Aztreonam in the treatment of serious gram-negative infections. Current Therapeutic Research 36: 875, 1984Google Scholar
- Tsouroutsoglou W, Sion ML, Kapoulas S, Avramidou E, El Messidi M, et al. Aztreonam in serious gram-negative infections. Chemioterapia 4(Suppl. 1): 88, 1985Google Scholar
- Van Cangh PJ, Wauters G, Wese FX, Mathys B, Hodder RW. Tissue and serum levels of aztreonam in patients undergoing transurethral resection of the prostate. Abstract 330, 4th Mediterranean Congress of Chemotherapy, Greece, October 1984Google Scholar
- Van Laethem Y, Husson M, Klastersky J. Serum bactericidal activity of aztreonam, cefoperazine and amikacin, alone or in combination, against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 26: 224, 1984PubMedGoogle Scholar
- Watson AJS, Stout RL, Whelton A. The intrarenal distribution of aztreonam in healthy and diseased kidneys: clinical therapeutic implications 150: 631, 1984Google Scholar
- Webb DW, Wyle FA. Randomised comparative study of aztreonam and cefamandole in the treatment of urinary tract infection. Current Therapeutic Research 36: 113, 1984Google Scholar
- Whitney RR, Bonner DP, Olsen SJ, Miller BH, Sykes RB. Treatment of experimental Haemophilus influenzae meningitis with SQ26, 776. Abstract no. 888, ICAAC, Chicago 1985Google Scholar
- Winslade NE, Smith IL, Simons GW, Swanson BJ, Vigano A, et al. The pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis. Reviews of the Infectious Diseases 7(Suppl. 4): 756–763, 1985Google Scholar
- Wood MJ. Treatment of serious infections with aztreonam. In Williams & Woods (Eds) Aztreonam the antibiotic discovery for Gram-negative infections. Royal Society of Medicine International Congress and Symposium series No. 89, pp. 57–63, 1985Google Scholar
- Wu DH, Baltch AL, Smith RP. Effect of combinations of aztreonam with pipericillin or azlocillin on Pseudomonas aeruginosa. Abstract no. 32, ICAAC, Las Vegas, 1983Google Scholar